1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Shuda Xia
Shuda Xia
Articles (169) 

Stocks That Fell to 3-Year Lows in the Week of Feb. 9

Anheuser-Busch InBev SA/NV (BUD), CVS Health Corp. (CVS), Celgene Corp. (CELG), and Allergan PLC. (AGN) have declined to their respective three-year lows

February 11, 2018 | About:

Anheuser-Busch InBev SA/NV (NYSE:BUD), CVS Health Corp. (NYSE:CVS), Celgene Corp. (NASDAQ:CELG), and Allergan PLC. (NYSE:AGN) have declined to their three-year lows.

Anheuser-Busch InBev SA/NV (NYSE:BUD) declined to $103.15

The prices of Anheuser-Busch InBev (NYSE:BUD) shares have declined to $103.15 on Feb. 9, which is only 4.7% above the 3-year low of $98.28.

Anheuser-Busch InBev is a Brazilian-Belgian international beverage and brewing company. The company is the world’s largest brewer and is considered one of the largest fast-moving consumer goods companies in the world. The company was enlarged in October of 2016 when the company purchased SABMiller and concluded a merger. The company is expected to have an estimated global market share of 28%.

Anheuser-Busch InBev has a market cap of $172.84 billion; its shares were traded around $103.15 with a P/E ratio of 35.50 and P/S ratio of 3.08. The trailing 12-month dividend yield of Anheuser-Busch InBev stocks is 3.93%. The forward dividend yield of Anheuser-Busch InBev stocks is 3.91%. Anheuser-Busch InBev had an annual average earnings growth of 6.40% over the past 10 years.

On Jan. 9 Anheuser-Busch InBev announced that it has completed the pricing of EUR 4.25 billion aggregate principal amount of notes. The notes were issued on Jan. 23 and comprise of three different series. The three series include a 6.25 year floating rate notes due 2024, a 9 year 1.15% notes due 2027, and a 17 year 2.00% notes due 2035.

CVS Health Corp. (NYSE:CVS) declined to $69.39

The prices of CVS Health Corp. (NYSE:CVS) shares have declined to $69.39 on Feb. 9, which is only 4.2% above the 3-year low of $66.45.

CVS Health Corp. is an American retail pharmacy and health care company that grew from the parent company Mark Steven Inc. The business began as a chain of health and beauty aid stores but within several years pharmacies were added. The company owns several subsidiaries, including CVS Pharmacy, MinuteClinic, Caremark Rx, Longs Drugs, Omnicare, and Navarro Discount Pharmacies. The company ranked seventh on the Fortunes 500 and eighteenth on the Fortune Global 500 in 2017.

CVS Health Corp. has a market cap of $70.3 billion; its shares were traded around $69.39 with a P/E ratio of 14.38 and P/S ratio of 0.40. The trailing 12-month dividend yield of CVS Health Corp. stocks is 2.86%. The forward dividend yield of CVS Health Corp. stocks is 2.83%. CVS Health Corp. had an annual average earnings growth of 11.30% over the past 10 years.

On Feb. 8 CVS Health Corp. reported fourth quarter results. Fourth quarter year-over-year net revenues increased 5.3% to $48.4 billion while GAAP diluted earnings per share were $3.22. Adjusted earnings per share were $1.92 excluding $1.5 billion income tax benefit resulting from tax reform. For the full year, net revenues increased 4.1% to $184.8 billion compared to last year and GAAP diluted earnings per share were $6.45.

Celgene Corp. (NASDAQ:CELG) declined to $92.51

The prices of Celgene Corp. (NASDAQ:CELG) shares have declined to $92.51 on Feb. 9, which is only 3.9% above the 3-year low of $88.87.

Celgene Corp. is an American biotechnology company that researches, develops, and commercializes treatments relating to cancer and inflammatory disorders. The company’s major product is Revlimid, which in combination with dexamethasone treats multiple myeloma in patients. Revlimid is sold through proprietary risk management distribution programs to ensure safe and appropriate use.

Celgene Corp. has a market cap of $69.58 billion; its shares were traded around $92.51 with a P/E ratio of 25.84 and P/S ratio of 5.76. Celgene Corp. had an annual average earnings growth of 21.40% over the past 5 years.

On Feb. 9 Celgene Corp. announced the successful pricing of four series of senior unsecured notes for an aggregate principal amount of $4.5 billion. Of these notes, $500 million will mature in 2021 and will bear interest at an annual rate of 2.875%, while $1.0 billion will mature in 2023 and bear interest at an annual rate of 3.25%. The net proceeds from the offering will be used to finance a portion of the acquisition of Juno Therapeutics Inc. and to pay fees and expenses associated with the offering.

Allergan PLC. (NYSE:AGN) declined to $162.77

The prices of Allergan PLC. (NYSE:AGN) shares have declined to $162.77 on Feb. 9, which is only 2.7% above the 3-year low of $158.34

Allergan PLC. is an Irish international pharmaceutical company that produces both branded and generic drugs and performs pharmaceutical research and development. The company’s key products include Actonel, Acuvail, Aczone, Lumigan, Namenda, Ozurdex, and Rapaflo.

Allergan PLC. has a market cap of $54.13 billion; its shares were traded around $162.77 with and P/S ratio of 3.46. The trailing 12-month dividend yield of Allergan PLC. stocks is 1.74%. The forward dividend yield of Allergan PLC. stocks is 1.71%.

On Feb. 9 Allergan PLC. announced that its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28 to shareholders of record at the close of business on Feb. 28.

Disclosure: I do not own stock in any of the companies mentioned in the article.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Shuda Xia


User Generated Screeners


NorvasValDivid
mjspencerhiccups
DBrizan20Jul2018 DIV 1025p
DBrizan20Jul2018 927p
chetanj_pvgcj1534
mgr1929sd
haldrobekPredictablePriceUnder50NoOTC
haldrobekPredictablePriceUnder50
chrislphillipsf score
chandra3_16No Debt Graham
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK